A genomic approach to therapeutic target validation identifies a glucose-lowering <i>GLP1R</i> variant protective for coronary heart diseaseRobert A. Scott, Thomas Foltynie, Hanieh Yaghootkar et al.|Science Translational Medicine|2016Cited by 119
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trialBenjamin A. Fisher, K Turner, Tonny Veenith et al.|UCL Discovery (University College London)|2022Cited by 58
CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adultsTonny Veenith, Simon Gates, Benjamin A. Fisher et al.|BMJ Open|2021Cited by 6
CATALYST trial protocol: A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adultsTonny Veenith, Simon Gates, Benjamin A. Fisher et al.|medRxiv|2021Cited by 4
RBTT-06. TESSA JOWELL BRAIN MATRIX STUDY: A BRITISH FEASIBILITY STUDY OF MOLECULAR STRATIFICATION AND TARGETED THERAPY TO OPTIMIZE THE CLINICAL MANAGEMENT OF PATIENTS WITH GLIOMAColin Watts, S. Bowden, John Apps et al.|Neuro-Oncology|2019Cited by 2